title: Pharmacist initiation of postexposure doxycycline for Lyme disease prophylaxis.
abstract: OBJECTIVES To enhance public access to prophylaxis for Lyme disease following an identified Ixodes scapularis tick bite through pharmacist-initiated antibiotic therapy and to assess patient satisfaction with the pharmacy-based service provided. SETTING Independent community pharmacy in Charlestown, RI, from May to October 2012. PRACTICE DESCRIPTION Under a collaborative practice agreement, trained pharmacists at an independent pharmacy identified patients eligible for postexposure antibiotic prophylaxis following attachment and removal of an I. scapularis tick (commonly known as a deer tick) and dispensed two 100 mg tablets of doxycycline. Patients were included if they were 18 years or older, provided informed consent, had an estimated time of tick attachment of 36 hours or more, had the tick removed within 72 hours of visit, denied contraindications to doxycycline therapy, and reported telephone access for follow-up. Patients enrolled in the study protocol were given counseling related to doxycycline, signs and symptoms of Lyme disease, and future tick prevention strategies. PRACTICE INNOVATION Pharmacist initiation of doxycycline prophylaxis has not been described in the literature previously. Successful pharmacist initiation of antibiotic prophylaxis may have broader implications for states with endemic Lyme disease or other infectious disease public health concerns. MAIN OUTCOME MEASURES Patient self-reported adverse outcomes and satisfaction with the pharmacy-based service. RESULTS Eight patients enrolled in the study and completed the follow-up survey. The results indicated a high level of satisfaction with the pharmacy services provided, with no reports of the subsequent development of Lyme disease symptoms or major adverse events. CONCLUSION The project has expanded to three community pharmacy sites in southern Rhode Island based on this experience. Similar pharmacy-based collaborative practice models should be considered in highly endemic Lyme disease areas.
authors.forename: Anita N
authors.initials: AN
authors.lastname: Jackson
authors.forename: K Kelly
authors.initials: KK
authors.lastname: Orr
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Bratberg
authors.forename: Frederic
authors.initials: F
authors.lastname: Silverblatt
mesh_terms: D000328:Adult; D000818:Animals; D019072:Antibiotic Prophylaxis / Q000379:methods; D001733:Bites and Stings / Q000188:drug therapy; D003157:Community Pharmacy Services; D003299:Cooperative Behavior; D004318:Doxycycline / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018884:Ixodes / Q000187:drug effects; D008193:Lyme Disease / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010594:Pharmacies; D010595:Pharmacists; D056990:Post-Exposure Prophylaxis / Q000379:methods; D055815:Young Adult
chemical_list: D004318:Doxycycline